Search Results - "Aujoulat, Olivier"

Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018) by Cottu, Paul, Coudert, Bruno, Perol, David, Doly, Anne, Manson, Julien, Aujoulat, Olivier, Barletta, Hugues, Chalabi, Nassera, Samelson, Laurence, Pivot, Xavier

“…There is a growing need for real-world data on cancer treatments usage, especially to assess compliance with recommendations. We developed a French project…”
Get full text

Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review by Hammami, Emna, Lamarque, Mathilde, Aujoulat, Olivier, Debliquis, Agathe, Drénou, Bernard, Harzallah, Inès

“…Abstract Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy that is deadly if not treated promptly. The treatment of choice in patients…”
Get full text

Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate by Ojeda-Uribe, Mario, Merieau, Sylvain, Guillon, Marie, Aujoulat, Olivier, Hinschberger, Olivier, Eisenmann, Jean-Claude, Kenizou, David, Debliquis, Agathe, Veyradier, Agnès, Chantrel, François

“…Drug-mediated thrombotic microangiopathy may cause life-threatening medical emergencies. Novel targeted therapies have dramatically changed the prognosis of a…”
Get full text

Successful rapid desensitization to the antibody–drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma by Fizesan, Marie, Boin, Christopher, Aujoulat, Olivier, Newinger, Georges, Ghergus, Dana, Watier, Hervé, Lustig, Hélène, Ojeda-Uribe, Mario

Get full text

Results of a Prospective Non-Randomized Trial Comparing the Efficacy of Voriconazole (Vor) and Posaconazole (Pos) As Primary Prophylactic Agents of Invasive Fungal Infections (IFI) in Acute Leukemic Patients by Ojeda-Uribe, Mario, Haby, Celine, Gravet, Alain, Berg, Catherine, Aujoulat, Olivier, Jeandidier, Eric, Lohmann, Caroline, Drenou, Bernard, Lesquerbault, Benoît

“…Abstract 1120 Between 2007–2010 we performed a monocentric non-randomized prospective study to compare Vor (orally or IV 200 mg b.i.d.) to Pos (orally 200 mg…”
Get full text

Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma by Fizesan, Marie, Boin, Christopher, Aujoulat, Olivier, Newinger, Georges, Ghergus, Dana, Watier, Hervé, Lustig, Hélène, Ojeda-Uribe, Mario

Get full text